Insight

Iván R. González: Meta – analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases

Photo from Iván R. González/X

Oct 4, 2024, 15:05

Iván R. González: Meta – analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:

“An excellent meta-analysis on the first-line treatment of NSCLC with EGFR mutation and brain metastases:

Key Findings

Systematic review of 24 RCTs (n=2682) comparing EGFR TKIs and combination therapies.
Bevacizumab + 1G TKI improved overall survival (HR: 0.704; 95% CI: 0.433-0.973).
Chemotherapy + 1G TKI also increased OS (HR: 0.682; 95% CI: 0.464-0.899).
3G TKIs showed no significant benefit in OS vs 1G TKIs (HR: 0.855; 95% CI: 0.511-1.198).
3G TKIs + chemotherapy showed the greatest improvement in OS (HR: 1.69) and PFS (HR: 2.13).
Intracranial control was better with 1G TKI and bevacizumab.

The combination of 3G TKIs and chemotherapy appears to be the most effective strategy. More comparative studies are needed.”

Iván R. González

Source: Iván R. González/X

First-line treatment of EGFR-mutated non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

Authors: Jietao Ma, Xiaoxue Pang, Shuling Zhang, Letian Huang, Li Sun and Chengbo Han

Iván R. González

Bevacizumab brain metastases cancer Chengbo Han combination therapies EGFR-mutation Iván R. González Jietao Ma Letian Huang Li Sun NSCLC OncoDaily Oncology Shuling Zhang Xiaoxue Pang

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage